Danish pharma leader in diabetes and obesity therapies
Weight-loss GLP-1 drugs are expanding beyond injections to pills in the US, UK and UAE. Major manufacturers report rising uptake and ongoing development, with Medicare and NHS access shaping pace and affordability. Private prescriptions and new formulations are widening access while competition accelerates.
A wave of AI-enabled tools is reshaping publishing, note-taking, and defense sectors. Beehiiv and Substack roll out chat-assisted publishing; Plaud ships AI-powered notetaking hardware; Mode Inc expands via acquisitions to crowdsource data labeling; Mach Industries pursues multiple weapons programs to boost U.S. defense capabilities.
A wave of AI-driven restructuring is redefining how companies run global operations. Opendoor is moving operational work back to the U.S., signaling a broader shift toward leaner, AI-enabled workflows that compress offshore back offices and emphasize Services-as-Software. The changes echo across tech and outsourcing sectors as companies recalibrate headcount, partnerships, and location strategies.
A new weight‑loss pill version of semaglutide has launched in the UK for private prescriptions, offering an alternative to injections. The tablet requires strict dosing and a fasting routine and is not yet NHS‑funded. Several outlets warn about counterfeit pills as access broadens.
Anthropic has introduced Claude Science, a workspace that links Claude models to 60+ databases and specialized toolkits to automate life-sciences tasks. The platform includes a project-management workflow, sub-assistants, and a fact-checker to improve reproducibility. Early users report rapid genome browser creation and computational review pipelines.
The 340B program, which lets hospitals buy discounted outpatient drugs for low-income patients, is facing a new CMS rule changing reimbursement formulas to reduce payments by about 40%. The move aims to lower patient costs but could shrink hospital revenues and affect services and jobs. The rule follows an executive order in 2025 and reflects ongoing political battles between hospitals and the pharmaceutical industry.
Vivani Medical and Novo Nordisk are exploring a long-acting semaglutide implant to maintain weight loss, potentially replacing frequent injections. The device aims to release medicine steadily for months, pending clinical and regulatory validation.
Novo Nordisk has filed a US lawsuit accusing Eli Lilly of false advertising over weight-loss and diabetes drugs, claiming Lilly used outdated trial data to claim superiority. Lilly argues its ads rely on SURMOUNT-5 results and defends its campaigns. The case highlights a race for market share in GLP-1 obesity and diabetes treatments, with potential damages and corrective ads on the table.